The Zhitong Finance App learned that Hengrui Pharmaceutical (01276) rose more than 11% in early trading. As of press release, it rose 8.63% to HK$48.58, with a turnover of HK$112 million.

According to the news, Hengrui Pharmaceutical announced that revenue for the third quarter was 8.953 billion yuan, up 20.55% year on year; net profit to mother was 2,458 billion yuan, up 88.92% year on year, up 12% month on month. In the first three quarters, the company achieved operating income of 24.409 billion yuan, an increase of 5.26% over the previous year; net profit to mother was 6.923 billion yuan, an increase of 20.38% over the previous year.

It is worth noting that recently, Hengrui Pharmaceutical received a notice from the State Drug Administration. The company recently received a notice from the State Drug Administration that rimazolam toluene sulfonate for injection was approved as an additional indication for sedation during mechanical ventilation during intensive care. The drug has previously been approved domestically for sedation and anesthesia during non-tracheal intubation surgery/operation, and induction and maintenance of general anesthesia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.